Detalles de la búsqueda
1.
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
Cancer
; 129(5): 714-727, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36597662
2.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol
; 21(12): 1589-1601, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125909
3.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer
; 126(2): 373-380, 2020 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31769875
4.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959700
5.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27745820
6.
Osimertinib in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(20): 1993-4, 2017 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28514610
7.
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.
JTO Clin Res Rep
; 4(3): 100423, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36925644
8.
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
J Natl Cancer Inst
; 115(4): 437-446, 2023 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36625510
9.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Clin Cancer Res
; 29(17): 3340-3351, 2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379430
10.
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Clin Lung Cancer
; 23(1): 72-81, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34782240
11.
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Invest New Drugs
; 29(3): 499-505, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20094773
12.
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials.
J Natl Cancer Inst
; 113(11): 1460-1464, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33881547
13.
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Clin Lung Cancer
; 22(3): 178-186, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33358401
14.
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(9): 1368-1377, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264316
15.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
J Immunother Cancer
; 9(8)2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34429332
16.
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Clin Lung Cancer
; 22(3): 170-177, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33221175
17.
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
J Thorac Oncol
; 16(4): 601-609, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33388476
18.
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.
Expert Rev Respir Med
; 14(2): 125-136, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31829747
19.
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
Clin Lung Cancer
; 21(4): e294-e301, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32089476
20.
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
J Thorac Oncol
; 15(12): 1919-1927, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32916308